Prophylaxis of atrial fibrillation (AF)-related cardioembolism in oncology is often challenging [1]. The CHA2DS2-VASc score performs differently according to the presence or absence of cancer, with more thromboembolic and bleeding events occurring in subjects with than without malignancy and a CHA2DS2-VASc score
